Gilead Sciences, Inc. (GILD) Shares Bought by Tredje AP fonden

Tredje AP fonden grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 190,589 shares of the biopharmaceutical company’s stock after acquiring an additional 1,265 shares during the period. Tredje AP fonden’s holdings in Gilead Sciences were worth $14,369,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in GILD. Gulf International Bank UK Ltd grew its position in shares of Gilead Sciences by 0.4% during the 1st quarter. Gulf International Bank UK Ltd now owns 413,946 shares of the biopharmaceutical company’s stock worth $31,207,000 after buying an additional 1,744 shares during the period. King Luther Capital Management Corp grew its position in shares of Gilead Sciences by 30.4% during the 1st quarter. King Luther Capital Management Corp now owns 8,353 shares of the biopharmaceutical company’s stock worth $630,000 after buying an additional 1,948 shares during the period. Intact Investment Management Inc. acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $3,573,000. Timber Hill LLC grew its position in shares of Gilead Sciences by 10.2% during the 1st quarter. Timber Hill LLC now owns 44,893 shares of the biopharmaceutical company’s stock worth $3,384,000 after buying an additional 4,152 shares during the period. Finally, Cornerstone Capital Inc. grew its position in shares of Gilead Sciences by 2.5% during the 1st quarter. Cornerstone Capital Inc. now owns 64,516 shares of the biopharmaceutical company’s stock worth $4,864,000 after buying an additional 1,550 shares during the period. 77.72% of the stock is owned by institutional investors.

Shares of Gilead Sciences opened at $68.17 on Thursday, according to MarketBeat.com. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $89.54. The company has a market capitalization of $88.20 billion, a price-to-earnings ratio of 7.96, a P/E/G ratio of -5.90 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same period in the previous year, the firm posted $2.23 EPS. The business’s quarterly revenue was down 21.8% compared to the same quarter last year. analysts anticipate that Gilead Sciences, Inc. will post 5.75 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s payout ratio is currently 26.64%.

In other Gilead Sciences news, CFO Robin L. Washington sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the transaction, the chief financial officer now owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the completion of the transaction, the executive vice president now directly owns 69,426 shares in the company, valued at approximately $5,463,131.94. The disclosure for this sale can be found here. In the last ninety days, insiders sold 226,667 shares of company stock worth $17,060,854. Insiders own 1.30% of the company’s stock.

Several brokerages have recently commented on GILD. BidaskClub cut shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Barclays lowered their price target on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Leerink Swann set a $72.00 price target on shares of Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $88.14.

About Gilead Sciences

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply